[BidClub_]

SHOW DIRECTORY

No Priors

Elad Gil and Sarah Guo speak with leading AI engineers, researchers, and founders about model progress, markets at risk of disruption, and how commerce, culture, and society may change.

SOURCE DESCRIPTION · RSS

85 EPISODESENTRACKED SHOW
SUBSCRIBE[Feed_]
7 episodes2 active
Language
No PriorsEN · 43 min

Re-Founding Incumbents for the AI Era with Sequence Holdings Co-Founder and CEO Michael Lee

Sarah GuoMichael Lee

Sequence Holdings is pairing frontier engineering with incumbent advantages, partnering with the Dell family office on its $7.7B acquisition of Baldwin.At BankSouth, average consumer-loan underwriting volume fell 94%, timelines dropped from 30 days to 11, and Q2 loan volume doubled versus Q1 without changed standards.Whether Atlas can repeat that operating leverage depends less on code than on the more difficult human engineering problem.

No PriorsEN · 61 min

How Nuclear Will Unlock Energy Abundance with Valar Atomics Founder Isaiah Taylor

Sarah GuoIsaiah Taylor

Valar Atomics treats nuclear as a manufacturing problem, targeting a simple, intrinsically safe “Toyota Camry” rather than a bespoke paper reactor.DOE testing authority enabled its 100 kW W-250 to reach criticality, while passive heat removal and a seven-month milestone interval provide operating evidence.Equity-funded deployment could precede project finance, with AI as an initial catalyst and cheaper energy as the longer-term demand thesis.

No PriorsEN · 22 min

Amex Global Business Travel: The World’s First AI Take Private with Long Lake CEO Alexander Taubman

Elad GilAlexander Taubman

Long Lake has agreed to acquire American Express Global Business Travel for $6.3 billion, in what Sarah Guo believes may be the world’s first-ever AI take-private.Nexus reuses roughly 80% of infrastructure across 30 acquisitions, compressing AI deployment from more than a year to days, while acquired businesses reportedly moved from 0–5% to 20% or more organic growth; execution and the transaction remain key watchpoints.

No PriorsEN · 58 min

Jared Kushner: BrainCo, Affinity Partners, and the Geopolitics of AI

Jared KushnerSarah GuoElad Gil

Affinity Partners seeks returns through governance judgment, networks, and hands-on execution, while favoring Gulf and Latin American tailwinds and contrarian opportunities such as Albania.BrainCo is productizing reusable AI infrastructure for institutions, with a permitting workflow reduced from over 40 steps to 35 at over 90% accuracy; adoption, talent, project selection, and energy permitting remain key constraints.

No PriorsEN · 25 min

No Priors Ep. 116 | With Sarah and Elad

Sarah GuoElad Gil

AI leaders are emerging in foundation models, coding, medical scribing, and customer success, while sales productivity, financial-analyst tooling, accounting, and pharma remain open.The winning application playbook combines vertical workflows, proprietary data, distribution, and user-generated knowledge, while startup mergers may strengthen defense against incumbents; neglected fertility, longevity, and world-model opportunities remain constrained by financing, regulation, and uncertain commercialization.

No PriorsEN · 41 min

Predicting the Earth with Josh Goldman: How KoBold Uses AI to Find Critical Minerals

Sarah GuoElad GilJosh Goldman

KoBold treats mineral exploration as an information problem in an industry where discovery productivity has fallen roughly 10x, targeting $50–100 million per discovery against venture-scale returns.Mingomba’s core exceeds 5% copper versus roughly 0.6% at operating mines, while active learning and fragmented geological data support a pipeline constrained more by quality projects, permitting, and social license than capital.

No PriorsEN · 41 min

No Priors Ep. 104 | With Flagship Pioneering CEO and Co-Founder Noubar Afeyan

Sarah GuoNoubar Afeyan

Noubar Afeyan’s Flagship Pioneering model treats parallel startup creation as a repeatable institution for underwriting uncertainty, using variation, selection and iteration rather than forecasting breakthroughs.Generate Biomedicines has more than 15 computationally designed antibody programs, but Phase III trials, FDA regulation, pricing power and platform funding remain decisive constraints, as Joule’s technically successful but economically unviable outcome demonstrates.